NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Immutep Ltd. IMMP
10 fiscal years on record · AUD · FY2024 reported · SEC filings only
Growth
AUD 10.3M
Revenue, FY2024 · full 10-year series below
Revenue AUD M
Net income AUD M
FY2024 · Revenue 10.3 · Net income -61.4
Compound annual growth
Revenue compounded at −8.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−595 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Net -594.6%
ROE
FY2024 · ROE -36.9%
Each AUD of equity lost 37 cents this year.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · AUD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue AUD B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income AUD B | · | · | · | · | · | · | · | · | · | · |
| EBITDA AUD B | · | · | · | · | · | · | · | · | · | · |
| Income tax AUD B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income AUD B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| Free cash flow AUD B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted AUD | −0.04 | −0.04 | −0.04 | −0.04 | −0.05 | −0.03 | −5.29 | −4.63 | −0.40 | −2.78 |
| Dividend / sh AUD | · | · | · | · | · | · | · | · | · | · |
| Payout % | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | · |
| ROE % | −36.9 | −26.2 | −34.6 | −38.5 | −56.1 | −46.7 | −63.4 | −42.4 | −35.3 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 4 failures in 39 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 37 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente4 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015